It is generally considered that PD-1 plays a crucial role in regulating immune tolerance and PD-1 blockade therapy can reinvigorate pre-existing TILs that are reactive to neoantigens on tumor cells [45]. This evidence concerns the gene PDCD1 and neoplasm.